title: Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.
abstract: The optimal method for measuring cancer extent in prostate biopsy specimens is unknown. Seven hundred forty-four patients diagnosed between 1990 and 1996 with prostate cancer and managed conservatively were identified. The clinical end point was death from prostate cancer. The extent of cancer was measured in terms of number of cancer cores (NCC), percentage of cores with cancer (PCC), total length of cancer (LCC) and percentage length of cancer in the cores (PLC). These were correlated with prostate cancer mortality, in univariate and multivariate analysis including Gleason score and prostate-specific antigen (PSA). All extent of cancer variables were significant predictors of prostate cancer death on univariate analysis: NCC, hazard ration (HR) = 1.15, 95% confidence interval (CI) = 1.04-1.28, P = 0.011; PPC, HR = 1.01, 95% CI = 1.01-1.02, P < 0.0001; LCC, HR = 1.02, 95% CI = 1.01-1.03, P = 0.002; PLC, HR = 1.01, 95% CI = 1.01-1.02, P = 0.0001. In multivariate analysis including Gleason score and baseline PSA, PCC and PLC were both independently significant P = 0.004 and P = 0.012, respectively, and added further information to that provided by PSA and Gleason score, whereas NNC and LCC were no longer significant (P = 0.5 and P = 0.3 respectively). In a final model, including both extent of cancer variables, PCC was the stronger, adding more value than PLC (χ² (1df) = 7.8, P = 0.005, χ² (1df) = 0.5, P = 0.48 respectively). Measurements of disease burden in needle biopsy specimens are significant predictors of prostate-cancer-related death. The percentage of positive cores appeared the strongest predictor and was stronger than percentage length of cancer in the cores.
authors.affiliation: Centre for Molecular Oncology and Imaging, Queen Mary University of London, UK.
authors.forename: Ramzi
authors.initials: R
authors.lastname: Rajab
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Fisher
authors.forename: Michael W
authors.initials: MW
authors.lastname: Kattan
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Foster
authors.forename: Tim
authors.initials: T
authors.lastname: Oliver
authors.forename: Henrik
authors.initials: H
authors.lastname: Møller
authors.forename: Victor
authors.initials: V
authors.lastname: Reuter
authors.forename: Peter
authors.initials: P
authors.lastname: Scardino
authors.forename: Jack
authors.initials: J
authors.lastname: Cuzick
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Berney
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D001707:Biopsy, Needle; D015331:Cohort Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D010340:Pathology, Surgical / Q000379:methods* / Q000592:standards; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery
chemical_list: D017430:Prostate-Specific Antigen
references.citation: J Urol. 2004 Jun;171(6 Pt 1):2215-20
references.pmid: 15126788
references.citation: Urology. 2002 Sep;60(3):454-7
references.pmid: 12350483
references.citation: J Clin Oncol. 1999 Jan;17(1):168-72
references.pmid: 10458230
references.citation: Urology. 1998 May;51(5):759-64
references.pmid: 9610589
references.citation: BJU Int. 2008 Jul;102(1):24-7
references.pmid: 18341623
references.citation: Cancer. 1996 Sep 1;78(5):1079-84
references.pmid: 8780546
references.citation: BJU Int. 2010 Mar;105(6):818-23
references.pmid: 19751264
references.citation: J Clin Oncol. 2000 Mar;18(6):1164-72
references.pmid: 10715284
references.citation: Urology. 2007 Jun;69(6):1095-101
references.pmid: 17572194
references.citation: J Urol. 2004 Jun;171(6 Pt 1):2260-4
references.pmid: 15126798
references.citation: Am J Surg Pathol. 2003 Apr;27(4):432-40
references.pmid: 12657927
references.citation: Eur Urol. 2007 Sep;52(3):733-43
references.pmid: 17350750
references.citation: J Urol. 1996 Apr;155(4):1344-7
references.pmid: 8632570
references.citation: Eur Urol. 1999;36(1):21-30
references.pmid: 10364651
references.citation: J Urol. 2004 Jun;171(6 Pt 1):2209-14
references.pmid: 15126787
references.citation: Urology. 2003 Apr;61(4):742-7
references.pmid: 12670558
references.citation: Urology. 2002 Dec;60(6):1034-9
references.pmid: 12475665
references.citation: Br J Cancer. 2006 Nov 6;95(9):1186-94
references.pmid: 17077805
references.citation: J Urol. 1996 Oct;156(4):1375-80
references.pmid: 8808875
references.citation: J Urol. 1996 Sep;156(3):1059-63
references.pmid: 8709307
references.citation: Eur Urol. 2000 Apr;37(4):449-55
references.pmid: 10765076
references.citation: J Urol. 2003 Jun;169(6):2136-41
references.pmid: 12771735
references.citation: Urology. 1998 Dec;52(6):1079-84
references.pmid: 9836558
references.citation: Eur Urol. 2008 Oct;54(4):728-39
references.pmid: 18603352
references.citation: J Urol. 1998 Jun;159(6):2023-9
references.pmid: 9598511
references.citation: Urology. 2002 May;59(5):704-8
references.pmid: 11992844
references.citation: J Urol. 2009 Apr;181(4):1628-33; discussion 1633-4
references.pmid: 19233388
references.citation: Rev Urol. 2003;5 Suppl 3:S3-S13
references.pmid: 16985948
references.citation: Urology. 2008 Oct;72(4):887-91
references.pmid: 18329080
references.citation: Cancer. 1995 Jan 15;75(2):530-8
references.pmid: 7529129
references.citation: Urol Oncol. 2003 May-Jun;21(3):213-8
references.pmid: 12810209
references.citation: J Urol. 1996 Apr;155(4):1361-7
references.pmid: 8632575
references.citation: Eur Urol. 2009 Dec;56(6):891-8
references.pmid: 19683860
references.citation: JAMA. 1994 Feb 2;271(5):368-74
references.pmid: 7506797
references.citation: Urol Int. 2006;77(3):200-4
references.pmid: 17033205
references.citation: Urology. 1994 Sep;44(3):371-6
references.pmid: 7521093
references.citation: Scand J Urol Nephrol. 2009;43(2):109-13
references.pmid: 19242861
references.citation: Cancer. 1997 Nov 1;80(9):1852-6
references.pmid: 9351559
references.citation: Histopathology. 2008 Aug;53(2):177-83
references.pmid: 18752501
references.citation: BJU Int. 2008 Apr;101(7):809-16
references.pmid: 18321314
references.citation: Urology. 2000 Apr;55(4):572-7
references.pmid: 10736506
references.citation: Cancer. 2008 Oct 15;113(8):2068-72
references.pmid: 18792067
references.citation: Am J Surg Pathol. 2005 Sep;29(9):1228-42
references.pmid: 16096414
references.citation: Urology. 1999 Oct;54(4):689-93
references.pmid: 10510929